Sucralose affects response to oral glucose load in obese

Sucralose affects response to oral glucose load in obese
For obese adults who do not use non-nutritive sweetener, sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

(HealthDay)—For obese adults who do not use non-nutritive sweetener (NNS), sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

M. Yanina Pepino, Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues examined the acute effects of sucralose ingestion on the metabolic response to an oral glucose load in 17 obese individuals who did not use NNS and were insulin sensitive. In a randomized crossover design study, participants underwent a five-hour modified on two occasions 10 minutes after consuming sucralose or water.

The researchers found that sucralose ingestion caused significantly greater incremental increases in peak concentrations and insulin area under the curve, as well as a greater peak rate, and caused significant decreases in insulin clearance and insulin sensitivity, compared with the control condition. For active glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, glucagon incremental area under the curve, or indices of sensitivity to the ?-cell response to glucose, there were no significant differences between the conditions.

"In conclusion, the results from our study demonstrate that sucralose affects the glycemic and hormonal responses to an oral glucose load in obese people who do not normally consume NNS," the authors write. "These findings support the notion that sucralose is not metabolically inert but has physiologic effects."

Tate & Lyle provided sucralose for the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Bile acid sequestrant reduces glucose concentration in T2DM

Jan 30, 2013

(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, ...

Recommended for you

Blood glucose levels set for achieving HbA1c targets

Apr 11, 2014

(HealthDay)—The average self-monitored blood glucose (SMBG) concentrations needed at premeal, postmeal, and bedtime have been established to achieve a range of hemoglobin A1c (HbA1c) targets, according ...

Women with diabetes less likely to have a mammogram

Apr 11, 2014

Women with diabetes are 14 per cent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's ...

Nonalcoholic fatty liver disease linked to CKD in T1DM

Apr 09, 2014

(HealthDay)—For patients with type 1 diabetes, nonalcoholic fatty liver disease (NAFLD) is independently associated with the risk of incident chronic kidney disease (CKD), according to a study published ...

Common diabetes treatment could extend hypoglycaemia

Apr 08, 2014

(Medical Xpress)—Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycaemia, which ...

User comments